Can you believe SIGNIFOR LAR KIT received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6225284 | RECORDATI RARE | Somatostatin peptides |
Jun, 2016
(7 years ago) | |
| US7473761 | RECORDATI RARE | Somatostatin analogues |
Dec, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8822637 | RECORDATI RARE | Somatostatin analogues |
Aug, 2023
(8 months ago) | |
| US7759308 | RECORDATI RARE | Microparticles comprising somatostatin analogues |
Oct, 2026
(2 years from now) | |
| US9351923 | RECORDATI RARE | Extended-release composition comprising a somatostatin derivative in microparticles |
May, 2028
(4 years from now) | |
Signifor Lar Kit is owned by Recordati Rare.
Signifor Lar Kit contains Pasireotide Pamoate.
Signifor Lar Kit has a total of 5 drug patents out of which 2 drug patents have expired.
Expired drug patents of Signifor Lar Kit are:
- US8822637
- US6225284
Signifor Lar Kit was authorised for market use on 29 June, 2018.
Signifor Lar Kit is available in for suspension;intramuscular dosage forms.
Signifor Lar Kit can be used as method of treating disorders with an etiology comprising or associated with excess gh-secretion, method of treating acromegaly.
Drug patent challenges can be filed against Signifor Lar Kit from 14 December, 2016.
The generics of Signifor Lar Kit are possible to be released after 23 May, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-268) | Jun 29, 2025 |
| New Indication(I-785) | Jun 29, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 15, 2021 |
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2017 |
| New Product(NP) | Dec 15, 2017 |
| Orphan Drug Exclusivity(ODE-81) | Dec 15, 2021 |
Drugs and Companies using
PASIREOTIDE PAMOATE ingredient
NCE-1 date:
Market Authorisation Date:
29 June, 2018Treatment:
Method of treating acromegaly; Method of treating disorders with an etiology comprising or associated with excess gh-secretionDosage:
More Information on Dosage
SIGNIFOR LAR KIT family patents
